Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) Smolen, J. S., Schlichting, D. E., Sterling, K. L., Keystone, E., Taylor, P., Genovese, M. C., Johnson, L., Rizo Rodriguez, J. C., Lee, C. H., Gaich, C. L. WILEY-BLACKWELL. 2012: S214–S214
View details for Web of Science ID 000309748301029